Leading global digital health company Huma Therapeutics has acquired data driven clinical research and technology specialist Alcedis.
Through the acquisition, Huma will form an advanced clinical trials division offering digital solutions across the entire development pipeline, from early stage through to Phase IV hybrid and fully decentralized trials.
Integrating Alcedis鈥� clinical and operational know-how with Huma鈥檚 digital expertise will make Huma the optimal HealthTech provider, able to support the seamless integration of digital technology into clinical trials.
Alcedis has more than 25 years of clinical trial experience while Huma鈥檚 award-winning technologies have been deployed since 2011.
Could listed BiVictriX Therapeutics deliver cancer breakthrough?
Between them, Huma and Alcedis have managed nearly a thousand studies across a wide range of therapeutic areas, including rare diseases, oncology, immunology, cardiovascular, respiratory, neurodegenerative, musculoskeletal, dermatology and metabolic diseases, in over 60 countries involving more than 650,000 participants.
Dan Vahdat, CEO and founder of Huma, said: 鈥淗uma has been a leader in digital-first care and research, partnering with health systems and pharma companies and now with this acquisition we鈥檙e set to redefine the clinical trials sector.鈥�
Hanno H盲rtlein, managing director of Alcedis, said: 鈥淲e are excited to be joining the Huma family, bringing our clinical trials expertise and capabilities to combine with those of Huma鈥檚 award-winning technology-platform. Together, we will offer substantially greater benefit to pharmaceutical, medtech, clinical research organisation, and academic partners for their research projects.鈥�
/news/at-home-hospital-scale-up-raises-92m/
Huma is听补苍听innovation partner to four national governments听鈥撎�England鈥檚 NHS, Wales, Germany and UAE听鈥� and its听digital 鈥榟ospital at home鈥� was co-created with clinicians and has been independently shown to almost double clinical capacity, reduce hospital readmissions by over a third and has patient adherence levels of over 90 per cent.听听
In 2021 Huma Therapeutics raised 拢92m to scale its modular platform for powering digital ‘hospitals at home’ nationally.